Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Blopress, Takepron to Go to Teva-Takeda Joint Venture
Takeda Pharmaceutical will transfer its major long-listed products collectively worth some 125 billion yen, including the hypertension drug Blopress (candesartan), to its joint venture with Israel’s Teva Pharmaceutical Industries, the two companies said on December 28. The products subject to…
To read the full story
Related Article
- Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
October 11, 2016
- Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
March 30, 2016
- Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
BUSINESS
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
- Linepharma to Rebrand as Nordic Pharma Japan from 2026
December 11, 2025
- Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
December 11, 2025
- Enhertu’s PIII Ovarian Cancer Trial Kicks Off for 1st-Line Maintenance Therapy
December 11, 2025
- Pfizer Files Hympavzi for Hemophilia with Inhibitors
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…